Pharmaceutical compositions and method for treating inflammation in cattle and other animals
Novel transdermal preparations combining a non-steroidal anti-inflammatory drug (NSAID) such as flunixin, are disclosed. Methods for using and administering such preparation in the treatment of inflammatory conditions in bovines, including bovine respiratory disease, are also disclosed.
1. A transdermal liquid preparation for administration to cattle comprising:
a) a first and a second dermal penetration enhancer;
b) an aprotic primary solvent; and
c) a therapeutically effective amount of flunixin meglumine;
wherein the first dermal penetration enhancer is menthol;
the second dermal penetration enhancer is a mixture of saturated or unsaturated fatty acid esters or diesters of propylene glycol and glycerol; wherein the first dermal penetration enhancer comprises from about 2 to about 20% w/v of the transdermal liquid preparation; and
the aprotic primary solvent is 2-pyrrolidone.
2. The transdermal liquid preparation of claim 1 , wherein the first dermal penetration enhancer comprises from about 5 to about 15% w/v of the transdermal liquid preparation.
3. The transdermal liquid preparation of claim 1 , wherein the second dermal penetration enhancer comprises from about 2 to about 50% w/v of the transdermal liquid preparation.
4. The transdermal liquid preparation of claim 1 , wherein the transdermal liquid preparation comprises from about 1 to about 20% by wt of flunixin active.
5. The transdermal liquid preparation of claim 1 , wherein the aprotic primary solvent comprises from about 5 to about 90% by wt of the transdermal liquid preparation.
6. The transdermal liquid preparation of claim 1 , further comprising a second vehicle or solvent comprising up to about 80% by wt of the transdermal liquid preparation.
7. The transdermal liquid preparation of claim 6 , wherein the second vehicle or solvent is water, ethanol, isopropanol, 1,2-propanediol, glycerin, benzyl alcohol, dimethylisosorbide, triacetin, propylene glycol, glycol ethers, ethyl lactate and/or mixtures thereof.
8. The transdermal liquid preparation of claim 7 , wherein the glycol ether is selected from the group consisting of ethylene glycol monoethyl ether, diethylene glycol monoethyl ether, and/or dipropylene glycol monoethyl ether.
9. The transdermal liquid preparation of claim 1 , further comprising a second pharmaceutically active compound.
10. The transdermal liquid preparation of claim 9 , wherein the second pharmaceutically active compound is selected from the group consisting of antimicrobials, anti-inflammatory agents, oxytocin, hormones for reproduction, growth enhancement compounds, physiologic intervention compounds, anxiolytic compounds, antihistamines, immune stimulants, and vaccines.
11. A transdermal liquid preparation of claim 1 , comprising:
a) from about 5% to about 15% by wt of said first dermal penetration enhancer;
b) from about 2% to about 50% by wt of said second dermal penetration enhancer;
c) from about 5% to about 15% of said flunixin based on free acid content;
d) from about 5% to about 90% of said aprotic primary solvent; and
e) up to about 80% of a second vehicle or solvent.
12. A method of treating inflammatory conditions, comprising administering an effective amount of a transdermal liquid preparation of claim 1 to an animal in need thereof.
13. The method of claim 12 , wherein the amount of flunixin administered is from about 1 to about 5 mg/kg active content.
14. The method of claim 12 , further comprising administering a second pharmaceutical agent to said animal in need thereof.
15. The method of claim 14 , wherein the second pharmaceutical agent is selected from the group consisting of antimicrobials, anti-inflammatory agents, oxytocin, hormones for reproduction, growth enhancement compounds, physiologic intervention compounds, anxiolytic compounds, antihistamines, immune stimulants, and vaccines.
16. A method of administering the transdermal liquid preparation of claim 1 comprising
a) incorporating said transdermal liquid preparation into a press-in bottle application device, and
b) administering an effective amount of said transdermal liquid preparation to an animal in need thereof.
17. The transdermal liquid preparation of claim 1 , wherein
the propylene glycol diester is propylene glycol dicaprylate/dicaprate.